Mylan signs U.S. license deal on Humira with AbbVie

AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie’s blockbuster drug Humira, in a move that will give it more near-term control over the competition.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply